ME/CFS debates attended[edit | edit source]
|“|| We need a commitment from the Minister to increase the sparse funding for ME research, which at present stands at a paltry £1 for every sufferer. The now widely discredited PACE trial had far-reaching implications. Not only did it add to the existing myths around ME, but it led to alterations in the application of benefits and eligibility for social care.
—Emma Lewell-Buck MP, 24 Jan 2019
Talks and interviews[edit | edit source]
Online presence[edit | edit source]
See also[edit | edit source]
- Myalgic encephalomyelitis
- UK Parliament Commons Chamber debate 24th January 2019
- UK Parliament Grand Committee Room debate 21st June 2018
Learn more[edit | edit source]
References[edit | edit source]
- Hansard (January 25, 2019). "Appropriate ME Treatment - UK Parliament". hansard.parliament.uk. Retrieved January 25, 2019.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.